AcetaZOLAMIDE TABLETS USP
Acetazolamide, an inhibitor of the enzyme carbonic anhydrase, is a white to faintly yellowish white crystalline, odorless powder, weakly acidic, very slightly soluble in water and slightly soluble in alcohol.
Acetazolamide is indicated for the following:
For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure.
Published Studies Related to Acetazolamide
Patients with obstructive sleep apnea syndrome benefit from acetazolamide during an altitude sojourn: A randomized, placebo-controlled, double-blind trial. [2011.06.09]
Abstract BACKGROUND: Many patients with obstructive sleep apnea syndrome (OSA) are unable or not willing to use CPAP therapy when traveling to the mountains for work or recreation although they risk pronounced hypoxemia and exacerbation of sleep apnea. Since the treatment of OSA at altitude has not been established we tested the hypothesis that acetazolamide improves hypoxemia, sleep and breathing disturbances in otherwise untreated OSA patients at altitude... CONCLUSIONS: In OSA patients discontinuing CPAP during an altitude sojourn, acetazolamide improves oxygenation, breathing disturbances and sleep quality by stimulating ventilation. Therefore, OSA patients may benefit from acetazolamide at altitude if CPAP therapy is not feasible. Trial registration: ClinicalTrials.gov NCT00714740.
Effects of acetazolamide and dexamethasone on cerebral hemodynamics in hypoxia. [2011.05]
Previous attempts to detect global cerebral hemodynamic differences between those who develop headache, nausea, and fatigue following rapid exposure to hypoxia [acute mountain sickness (AMS)] and those who remain healthy have been inconclusive. In this study, we investigated the effects of two drugs known to reduce symptoms of AMS to determine if a common cerebral hemodynamic mechanism could explain the prophylactic effect within individuals...
Spironolactone does not prevent acute mountain sickness: a prospective, double-blind, randomized, placebo-controlled trial by SPACE Trial Group (spironolactone and acetazolamide trial in the prevention of acute mountain sickness group). [2011.03]
OBJECTIVES: Over the last 20 years a number of small trials have reported that spironolactone effectively prevents acute mountain sickness (AMS), but to date there have been no large randomized trials investigating the efficacy of spironolactone in prevention of AMS. Hence, a prospective, double-blind, randomized, placebo-controlled trial was conducted to evaluate the efficacy of spironolactone in the prevention of AMS... CONCLUSIONS: Spironolactone (50 mg BID) was ineffective in comparison to acetazolamide (250 mg BID) in the prevention of AMS in partially acclimatized western trekkers ascending to 5000 m in the Nepali Himalaya. Copyright (c) 2011 Wilderness Medical Society. Published by Elsevier Inc. All rights reserved.
Prospective, double-blind, randomized, placebo-controlled comparison of acetazolamide versus ibuprofen for prophylaxis against high altitude headache: the Headache Evaluation at Altitude Trial (HEAT). [2010.09]
OBJECTIVE: High altitude headache (HAH) is the most common neurological complaint at altitude and the defining component of acute mountain sickness (AMS). However, there is a paucity of literature concerning its prevention. Toward this end, we initiated a prospective, double-blind, randomized, placebo-controlled trial in the Nepal Himalaya designed to compare the effectiveness of ibuprofen and acetazolamide for the prevention of HAH... CONCLUSIONS: Ibuprofen and acetazolamide were similarly effective in preventing HAH. Ibuprofen was similar to acetazolamide in preventing symptoms of AMS, an interesting finding that implies a potentially new approach to prevention of cerebral forms of acute altitude illness. Copyright 2010 Wilderness Medical Society. Published by Elsevier Inc. All rights reserved.
Arterial [H+] and the ventilatory response to hypoxia in humans: influence of acetazolamide-induced metabolic acidosis. [2010.01]
In this study, we investigated possible separate effects of H+ ions and CO2 on hypoxic sensitivity in humans. We also examined whether hypoxic sensitivity, conventionally defined as the ratio of (hypoxic - normoxic) ventilation over (hypoxic - normoxic) Hb oxygen saturation can also be estimated by taking the ratio (hypoxic - normoxic) ventilation over (logPa(O2) hypoxia - logPa(O2) normoxia), enabling one to measure the hypoxic response independently from potential confounding influences of changes in position of the Hb oxygen saturation curve...
Clinical Trials Related to Acetazolamide
Tadalafil and Acetazolamide Versus Acetazolamide in Acute Mountain Sickness Prevention [Recruiting]
To evaluate the additive value of tadalafil given together with Diamox (acetazolamide) in
preventing acute mountain sickness in travelers to high altitude areas.
Acetazolamide's Headache Inducing Characteristics and Effects on the Cerebral Arteries and Blood Flow [Recruiting]
In this study the investigators will research the hypothesis that the drug Acetazolamide
induce headache and dilation of cerebral arteries and increase the cerebral blood flow in
the areas of the brain supplied by these arteries.
Comparison Between Effect of Acetazolamide and NaHco3 in Prevention of Contrast Nephropathy [Completed]
The purpose of this study is whether Acetazolamide is effective in prevention of contrast
A Trial of Acetazolamide Versus Placebo in Preventing Mountain Sickness During Rapid Ascent [Recruiting]
Acute mountain sickness is a common ailment in people venturing over 2500 m altitude.
Pilgrims to high altitudes are at an added risk since they are unaware and they gain height
faster than the recommendations. Acetazolamide is the standard treatment and prophylaxis of
acute mountain sickness. There are no randomized controlled trials that have studied
protective effects of Acetazolamide in rapid ascent, and there are few conflicting studies
regarding this matter.
This study is a randomized, double blinded, placebo controlled trial of Acetazolamide versus
placebo in 380 healthy individuals travelling to Gosaikunda Lake of Nepal in rates of ascent
that are faster than the recommendations. Acetazolamide 125 mg twice daily and a placebo
will be randomly assigned for 3 days and participants will be assessed at 3 stations.
This study will undertake to establish the role of Acetazolamide in Rapid Ascent and will be
the first RCT done in this issue.
The investigators hypothesize that Acetazolamide 125mg twice daily given before rapid ascent
to high altitude in Nepalese pilgrims will not be superior to placebo in decreasing both the
incidence and severity of acute mountain sickness.
Comparing Eye Pressure Using Maximal Tolerated Local Therapy or Systemic Acetazolamide [Recruiting]
Local therapy for glaucoma is known to induce a conjunctival inflammation. Because of this,
trabeculectomy is more likely to fail. The investigators exchange the local therapy by
systemic therapy using acetazolamide and measure the eye pressure using local therapy and
systemic therapy using acetazolamide. The investigators suspect an elevated eye pressure
using acetazolamide compared to local therapy. In summary acetazolamide could be a better
choice in reference to conjunctival inflammation, but a worse choice in reference to
controlling eye pressure.
Reports of Suspected Acetazolamide Side Effects
Intraocular Pressure Increased (9),
Eye Oedema (8),
Vision Blurred (7),
Drug Ineffective (6),
Acute Generalised Exanthematous Pustulosis (3),
Cataract Operation (3),
Visual Acuity Reduced (2),
Urinary Bladder Haemorrhage (2), more >>
Page last updated: 2011-12-09